Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $76.1 million.

  • Eton Pharmaceuticals' Liabilities and Shareholders Equity rose 191.59% to $104.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.3 million, marking a year-over-year increase of 181.37%. This contributed to the annual value of $76.1 million for FY2024, which is 139.83% up from last year.
  • Eton Pharmaceuticals' Liabilities and Shareholders Equity amounted to $76.1 million in FY2024, which was up 139.83% from $31.7 million recorded in FY2023.
  • Over the past 5 years, Eton Pharmaceuticals' Liabilities and Shareholders Equity peaked at $76.1 million during FY2024, and registered a low of $25.0 million during FY2022.
  • In the last 3 years, Eton Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $31.7 million in 2023 and averaged $44.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first decreased by 8.87% in 2022, then spiked by 139.83% in 2024.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Liabilities and Shareholders Equity stood at $26.3 million in 2020, then increased by 4.35% to $27.5 million in 2021, then fell by 8.87% to $25.0 million in 2022, then increased by 26.81% to $31.7 million in 2023, then skyrocketed by 139.83% to $76.1 million in 2024.